Next-Generation (R & D) Biologics market is worth $12. 17bn in 2018 & projections of revenue until 2024

Market Research Report & Industry Analysis Reports (PRNewsFoto/RnRMarketResearch)jwplayer.key="2kY/GKwZ2uQZmDlQ9VYArfZt2b4+KhHX3+DM4zisgtE=";DALLAS, June 11, 2014 /PRNewswire-iReach /-Next-generation biologics will address shortcomings in current therapies, including inconvenient dosing and concerns over side effects.) Developmental trends include sustained release, for less-frequent dosing, and reformulations for oral and topical administration. This study predicts the next-generation biologics market will reach $12 17bn worldwide in 2018, and then multiply in revenues to 2024.

Emerging biological drugs - discover R & D, business analysis, and revenue forecasts

What's the future of biologics, especially new drug classes? Now get the latest technological and commercial analysis. Staying ahead in data and knowledge, you benefit your authority. And you explore trends, developments, results, opportunities, and sales predictions.

So vision gain's new report shows you what's possible for biological drugs - their next phase. Avoid missing out there. Instead find progress in that industry and market, discovering expected progress and revenues. See how you can gain now.

New biotechnological medicines will benefit patients and pharmaceutical companies. Read on to explore those therapies, hearing how high revenues can go.

Leading Companies in next-generation biologics market are:Roche, Eli Lilly, Novo Nordisk, Sanofi, Pfizer, Kyowa Hakko Kirin, Baxter International.

Order to purchase copy @ http://www.rnrmarketresearch.com/contacts/purchase?rname=185532.

Forecasting and other information showing the most lucrative possibilities for treatments that study gives you sales forecasts to 2024 en overall submarket, product, world, and national level. See what the future holds, assessing gains for developers and producers. Many opportunities exist. And besides giving revenue predictions, that new analysis shows recent results, growth rates, and market shares. There you discover 94 tables, 55 charts, and two interviews with authorities in the biopharmaceuticals sector. And the following sections explain what our new investigation gives you.

Analyses exclusive to that study, showing the most important commercial potentials
Discover what's really going on. Our forecasting system goes to the core of the biopharmaceutical industry's sales potential like no other work, giving revenue predictions and their meanings. That analysis benefits plans, decisions, and influence by medical interpreting your needs, R & D, and companies' abilities.

Prospects for the world market and submarkets - what's possible for pharma biotechnology?
In report, discover overall world sales to 2024 for biologics and new therapies, with discussions.

Individual revenue predictions to 2024 for 17 next-generation biologic submarkets at world level:

Regenerative medicine, with submarket breakdowns for tissue engineering, stem cells, and gene therapies Antibodies, including monoclonal antibodies (mAbs), with sub-forecasting for antibody-drug conjugates (ADCs), engineered bispecific Antibody agents fragments and antibody-like protein (ALP) platforms Biosimilars (follow-on protein products).And discover other segments' forecasts to 2024:

Insulins, with submarkets for ultra-long acting, oral, and ultra-rapid-acting insulins Growth hormones Recombinant coagulation factors Other types of next-stage therapeutic proteins.Product forecasts for new forms, variations, and use of biological therapy
how will individual drugs perform to 2024 at world level? This report predicts revenues of seven top brands & those seven therapies will earn combined revenue of more than $10bn in 2024:

Adcetris Kadcyla Gazyva Tresiba Afrezza Plegridy EloctateGet complete report details @ http://www.rnrmarketresearch.com/next-generation-biologics-rd-industry-and-market-2014-2024-market-report.html.

The report explains trends, processes, and events affecting the biopharma industry and market from 2014, including these forces:

Limitations of existing biologics Promise of next-generation biologics, and product launches Extension of half-life series - pegylation and other technologies Demand rising for biological therapies Contract manufacturers (CMOs) serving those developmental needs and trends.And you explore these influences, among others:

Disease incidence affecting demand for those more-developed medicines Improvements in therapeutic antibodies, including targeted cytotoxic therapies R & D pipelines - e.g. for immunotoxins - including agents in clinical development Biosimilar insulins likely from 2015 - transformation of that market Effects of rising incidence rates in cancer, diabetes, and cardiovascular disorders.In three main ways our new investigation helps you gain recognition for insight, with data found only there:

Revenues to 2024 at world level, for 17 submarkets, and 7 products - explore outlooks for production, marketing, and sales Forecasts to 2024 for 9 national markets in North America, Europe, and Asia - assess countries for revenues and sales expansions Prospects for established competitors, companies, and new entrants rising - investigate portfolios, results, strategies, R & D, and opinions from interviews.Following companies are mentioned in this report:

3SBio, Aastrom Biosciences, AbbVie, Abcam, Ablynx, ADC Therapeutics and Adnexus (part of Bristol-Myers Squibb), Adocia, Advanced Cell Technology, Advantagene, Affibody and Agence Nationale de sécurité du Médicament et des produits de santé (ANSM), Alcon (part of Novartis)
Alexion Pharmaceuticals, Alfacell (now Tamir Biotechnology), Alkermes, Allergan, Allozyne, Ambrx, Amgen, AMRI, AnGes, Applied Genetic Technologies (AGTC), Ark Therapeutics, Astellas Pharma, AstraZeneca, Athersys, Medical Avita, Babraham Institute, Baxter International, Bayer Healthcare, Belrose Pharma, Benda Pharmaceutical, Biocad, BioCancell Therapeutics, Biocon, Biodel, Biogen Idec, Bioheart, BioMarin Pharmaceutical, Biopartners (part of Bioton), Biotest, Bioton, BioVex Group (part of Amgen), BioWa (part of Kyowa Hakko Kirin), bluebird bio, Boehringer Ingelheim, BrainStorm Cell Therapeutics, Bristol-Myers Squibb, Capricor Therapeutics, Cardio3 BioSciences, Cardium Therapeutics, Catalent Pharma Solutions, Celgene, Celladon, CellCoTec & other.

Browse more reports on Biopharmaceuticals Market at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/biopharmaceuticals.

About Us:

RnRMarketResearch.com is a database of selected syndicated market reports for global and Chinese industries including but not limited to life sciences, information technology & telecommunications, consumer goods, food and beverages, energy and power, automotive and transportation, manufacturing and construction, materials and chemicals, public sector as well as business and financial services. We provide 24/7 online and offline support to our customers. Call with your requirements or email the details on sales@rnrmarketresearch.com research.

Media Contact: Priyank Tiwari, RnRMarketResearch, + 18883915441, sales@rnrmarketresearch.com

Distributed by PR Newswire news iReach: https://ireach.prnewswire.com

SOURCE RnRMarketResearch

RELATED LINKS
http://www.rnrmarketresearch.com

reade more... Résuméabuiyad

Bioinformatics Market is Expected to Reach Revenue of $12.8 Billion Globally by 2020 - Allied Market Research

PORTLAND, Oregon, May 28, 2014 /PRNewswire/ --

Allied Market Research, today published a new market research report titled "Bioinformatics Market - Global Industry Analysis, Size, Growth Trends, Share, Opportunities and Forecast". As per the study, the global Bioinformatics market was valued at $3.4 billion in 2013, and it is expected to reach $12.8 billion by 2020. The market is expected to grow at a CAGR of 21.2% during 2014-2020.

Browse the full report at http://www.alliedmarketresearch.com/bioinformatics-market

Bioinformatics involves the development and storage methods that help in the organizing, analyzing, and retrieving of biological information. The development in the field of bioinformatics would help in various applications such as drug discovery and development, gene therapy, molecular medicine, preventive medicines, personalized medicines, etc. The factors driving the market are the need for integrated data, rising demand for drug development and discovery, the increasing focus in genomics & proteomics and favorable government initiatives. The limitations for the growth of this market are the need for skilled personnel, saturation of the pharmaceutical sectors and lack of common data formats. The factors that would provide opportunities for the growth of this market are standardization of databases, need for integration systems & solutions and need to control data overload.

The bioinformatics technology and services market is segmented into knowledge management tools, bioinformatics platforms and bioinformatics services. Bioinformatics platforms segment was estimated to be the highest revenue generating segment in 2013. This was due to increasing popularity of bioinformatics tools in various genomic studies. However, by 2020, knowledge management tools are expected to take over platform market and would emerge as the highest revenue generating segment in the overall bioinformatics technology and service market. This shift would be chiefly due to increasing need for data integration, increasing clinical trials and growth in the proteomic data. The services market is expected to have the highest potential during the analysis period due to increasing adoption of services by the biotechnology and pharmaceutical companies.

The bioinformatics market is segmented based on applications, namely metabolomics, molecular phylogenetics, transcriptomics, proteomics, chemoinformatics, genomics and others. The genomic application segment was estimated to be the major revenue generating segment in 2013; however, by 2020, chemoinformatics would supersede genomic. Major contributing factors for this growth are increasing application of drug discovery and development using bioinformatics tools, which proves to be cost and time efficient for the pharmaceutical companies. The transcriptomics market is expected to have the highest potential as they provide solution in multi target drug discovery, which reduces the risk of failure of hypothesis, aids in the discovery of drugs that helps in modulating various diseases, and provides various platforms in drug discovery.

Similar market studies by Allied Market Research -

Global Tissue Engineering and Regeneration Market - http://www.alliedmarketresearch.com/tissue-engineering-and-regeneration-market

Global Cardiac Biomarkers Market - http://www.alliedmarketresearch.com/cardiac-biomarkers-market

Global Forensic Technologies Market - http://www.alliedmarketresearch.com/forensic-technologies-market

The bioinformatics sector market is segmented based on medical bioinformatics, animal bioinformatics, agriculture bioinformatics, academics and others. The medical bioinformatics was and is projected to remain as the leading revenue generating market segment through 2020. The plunge would be due to the widespread application in preventive medicine, gene therapy and drug discovery & development using bioinformatics tools. The academics sector is forecast to be the potential segment, which is expected to grow at a CAGR of 38.5% during 2014-2020.

See all Diagnostics and Biotech market reports at - http://www.alliedmarketresearch.com/diagnostic-and-biotech-market-report

The geography market is segmented into North America, Europe, Asia Pacific and RoW. North America is the highest revenue generating region due to the widespread adoption of advanced technologies in the region. The Asia Pacific region is expected to have the highest growth potential during the analysis period and this is due the funding initiatives done by the government. In addition, many private players in the bioinformatics sector are entering the untapped regions to obtain large market share.

Principal strategies adopted by the manufactures are product launch, agreements and collaborations. Most of the agreements done are for the expansion of the product portfolio, example - Agilent technologies announced an agreement with SRI international. According to the agreement, the products of Agilent - GeneSpring GX, Mass Profiler Professional GeneSpring NGS and Pathway Architect version 12.5 with SRI International's complete BioCyc Pathway Database Collection would be offered as a combined package to the users. Thus, allowing end users to access, visualize, combine and analyze biological data.

The key companies profiled in this report are Accelrys, Inc., Affymetrix, Inc., Agilent technologies, Inc., Geneva bioinformatics, Non linear dynamics, Quest Diagnostics, Inc., Life Technologies corp., Illumina, Bruker Daltonics, inc., and Biomax informatics AG

About Us:

Allied Market Research (AMR) is a full-service market research and business consulting wing of Allied Analytics LLP, based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions". AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies, and this helps us in digging out market data that helps us generate accurate research data tables and confirm utmost accuracy in our market forecasting. All the data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of concerned domain. Our secondary data procurement methodology includes deep online and offline research and discussions with knowledgeable professionals and analysts in the industry.

Contact:
Sona Padman
5320 SW Macadam Avenue,
Suite 100, Portland, OR 97239
United States
Direct: +1(617)674-4143
Toll Free: +1(855)711-1555 (U.S. & Canada)
Fax: +1(855)550-5975

Email: sales@alliedmarketresearch.com

Web: http://www.alliedmarketresearch.com/

Blog: http://blog.alliedmarketresearch.com/

SOURCE Allied Market Research

reade more... Résuméabuiyad

WaferGen Bio-systems Reports Strong Revenue Growth for Q1 2014

FREMONT, Calif., May 8, 2014 /PRNewswire/ -- WaferGen Bio-systems, Inc. (OTCQB: WGBS) announced today its financial results for the first quarter ended March 31, 2014.

Key Highlights

Revenue for the first quarter of 2014 was $1.4 million, up 687% year over year Revenue for the first quarter of 2014 was 7.7% higher than the total revenue for fiscal year 2013 Net loss for the first quarter of 2014 was $2.5 million, compared to a net loss of $3.8 million in the first quarter of 2013 Cash balance at March 31, 2014 of $6.4 millionTotal revenue for the first quarter of 2014 was $1.4 million, up 687% from $179,000 in the first quarter of 2013.  Net loss for the first quarter of 2014 was $2.5 million, compared to a net loss of $3.8 million in the first quarter of 2013. The net loss reduction was primarily due to an increase in revenue of $1.2 million resulting in an increase in gross profit of $686,000 and a $1.6 million improvement in other income and expenses as a result of reduced interest expense and changes in derivative valuations, offset by a $1.0 million increase in operating expenses.

"We had a strong revenue performance in the first quarter across our product lines with a diverse customer base.  The rapid increase in adoption of our SmartChip platform was augmented by sales of the newly acquired Apollo business," said Ivan Trifunovich, President and CEO of WaferGen.  He added, "As previously disclosed, on January 6, 2014, we acquired substantially all of the assets of IntegenX's product line used in library preparation for NGS, including the Apollo 324TM instrument and PrepXTM reagents, which clearly put us in a strong competitive position.  In fact, the first quarter revenue was almost 8% higher than revenues for all of calendar year 2013, due to higher sales of the Smart Chip products and revenues from the newly acquired product lines.  Another important Q1 milestone was the launch of the SeqReadyTM version of the SmartChip TETM product, which drastically improves throughput and compresses the workflow in NGS sample preparation.  This new product contributed to sales into the clinical NGS market.  We are excited about our progress in the first quarter and we look forward to continuing the momentum as we further execute our growth strategy."

2014 Guidance

Based on our recent results and the successful integration of the IntegenX's product line used in library preparation for NGS, we are increasing the revenue guidance for full year 2014 to be in excess of $6M for 2014 from our prior guidance of in excess of $5 million.  Our net cash use is expected to be $750,000-$800,000 per month.

Investor Conference Call

As previously announced, management will host a conference call and live audio webcast to discuss its financial results for the quarter ended March 31, 2014, today at 5:00 pm ET, 2:00 PT.  Investors are invited to join the webcast and listen to the replay by clicking on the following link: http://public.viavid.com/index.php?id=109116.  In addition, interested parties may listen to the live broadcast by calling (877) 407-3982 for domestic participants and (201) 493-6780 for international participants.

About WaferGen

WaferGen Bio-systems, Inc. is an innovative life science company that offers innovative genomic solutions for clinical testing and research.  The SmartChip MyDesignTM Real-Time PCR System is a high-throughput genetic analysis platform for profiling and validating molecular biomarkers via microRNA and mRNA gene expression profiling, as well as single nucleotide polymorphism (SNP) genotyping.  The SmartChip TETM System is a novel product offering for target enrichment geared towards clinical Next-Gen sequencing (NGS).  The Company now also offers the Apollo 324TM product line used in library preparation for NGS.  These three complementary technologies offer a powerful set of tools enabling more accurate, faster and cheaper genetic analysis based on Next-Gen Sequencing and Real-Time PCR.

For additional information, please see http://www.wafergen.com

Forward Looking Statements

Certain statements made in this press release contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended that are intended to be covered by the "safe harbor" created by those sections.  Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "could," "seek," "intend," "plan," "estimate," "anticipate" or other comparable terms.  Forward-looking statements in this press release may address the following subjects among others: statements regarding the sufficiency of our capital resources, expected operating losses, expected revenues, expected expenses, expected cash usage and our expectations concerning our competitive position and business strategy.  Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our most recently filed Annual Report on Form 10-K and our subsequently filed Quarterly Reports on Form 10-Q.  We urge you to consider those risks and uncertainties in evaluating our forward-looking statements.  We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made.  Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

Investor Contacts:

ICR, Inc.
Bob Yedid
bob.yedid@icrinc.com
646-277-1250

Proactive Capital
Jeff Ramson
jramson@proactivecrg.com 
646-863-6893

WaferGen Bio-systems, Inc.
Stephen Baker 
stephen.baker@wafergen.com
510-780-2399

WAFERGEN BIO-SYSTEMS, INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Operations (Unaudited)

Gain (loss) on revaluation of derivative liabilities, net

Total other income and (expenses)

Net loss before provision for income taxes

Net loss attributable to common stockholders

Net loss per share - basic and diluted

Shares used to compute net loss per share - basic and diluted

WAFERGEN BIO-SYSTEMS, INC. AND SUBSIDIARIES

Condensed Consolidated Balance Sheets

Prepaid expenses and other current assets

Liabilities and Stockholders' Equity (Deficit)

Accrued payroll and related costs

Long-term debt, net of discount

Stockholders' equity (deficit):

Preferred Stock: $0.001 par value; 10,000,000 shares authorized; 2,944.7080 shares of Series 1 Convertible Preferred Stock issued and outstanding at March 31, 2014 and December 31, 2013

Common Stock: $0.001 par value; 300,000,000 shares authorized; 9,120,884 and 9,112,559 shares issued and outstanding at March 31, 2014 and December 31, 2013

Total stockholders' equity (deficit)

Total liabilities and stockholders' equity (deficit)

SOURCE WaferGen Bio-systems, Inc.

RELATED LINKS
http://www.wafergen.com

reade more... Résuméabuiyad